rvsvdelta-zebov-gp
Vaccineexperimental
Clinical trial activity
7 trials · 24 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started Nov 1, 2014 (NCT02283099)
Timeline
Indications
Mechanism of action
- MarburgvirusImmunity, active
Marburgvirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- rvsvdeltag-zebov
- rvsvdeltag-zebov gp
- rvsvdeltag-zebov-gp
- rvsvdelta-zebov-gp
- rvsvδg-zebov
- rvsvδg-zebov-gp
- rvsvδ-zebov-gp
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04822376 | Phase 2 | Oct 17, 2021 | Government of France |
| NCT05130398 | Phase 1/Phase 2 (Phase 2) | Apr 9, 2021 | Centre de Recherche Médicale de Lambaréné, Merck |
| NCT03161366 | Phase 3 | Jul 1, 2017 | Epicentre, Medecins Sans Frontieres |
| NCT02876328 | Phase 2 | Mar 31, 2017 | Institut National de la Santé Et de la Recherche Médicale, France, National Institute of Allergy and Infectious Diseases (NIAID), Redemption Hospital, The Liberia-US Clinical Trials Partnership Program, Partnership for Research on Ebola Virus in Liberia Project, University of London, University of Sierra Leone |
| NCT02788227 | Phase 2 | Jan 12, 2016 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT02378753 | Phase 2/Phase 3 (Phase 3) | Apr 1, 2015 | Centers for Disease Control and Prevention (CDC), Department of Health and Human Services, eHealth Africa, Government of Sierra Leone, University of Sierra Leone |
| NCT02283099 | Phase 1 | Nov 1, 2014 | Albert Schweitzer Hospital, Clinical Trial Center North, German Center for Infection Research, Philipps University of Marburg, University of Geneva, University of Hamburg, University of Tuebingen, Wellcome Trust, World Health Organization |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (24)
24 organizations
Page 1 / 2